The COMBAT Group invests heavily in clinical trials to prove the Safety, Efficacy and Delivery of our technologies.
We continue to work closely with clinicians on trials, evaluations and future developments to extend clinical use and optimise patient outcomes in an increasing number of disease areas.
We work collaboratively with clinicians to extend the use of PRS+ to maximise the effectiveness of HIPEC. The PRS is currently being evaluated and trialled in the following areas:
Ovarian Cancer – NCT02681432
A randomised 72 patient, phase III clinical trial in women with epithelial primary ovarian cancer (Stage FIGO II, III and IV) or tumour recurrence. Estimated completion 2018. Interim results from 72 patients presented in November 2017 show a 46% increase in mean survival and a 64% increase in disease free survival in the HIPEC group compared to the non HIPEC group.4
Colo-Rectal – HIPECT4 – NCT02614534
Multi centre, randomised, 200 patient phase II trial across 15 centres, evaluating the safety and efficacy of HIPEC with Mitomycin C (MMC) for treating locally advanced colorectal carcinoma. Expected completion 2020.
Pancreatic – Eurdract-2016-004298-41
A 42 patient, single centre, controlled, randomised, phase II trial using HIPEC with Gemcitabine in peritoneal carcinomatosis of pancreatic origin. Trial commenced 2017, expected completion 2020.
A collaboration with clinicians from the PRS working group to develop an independent and secure platform to record and analyse real world data. Helping to optimise HIPEC treatments across a range of disease areas.
Please contact us for more information on the current clinical programme.